Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07301216 · ClinicalTrials.gov registry record
Off Treatment Urinary Copper Excretion in Wilson Disease, Pilot Study
A clinical trial of Wilson Disease, sponsored by Yale University.
- Recruiting
- Registry status
- 30
- Enrollment target
- 1
- Study location
NCT07301216 is a study of Wilson Disease that is actively recruiting participants, run by Yale University. The registered enrollment target is 30 participants, below the 119-participant average among 4 other Wilson Disease trials with a reported enrollment target (75% lower). The trial reports 1 study location across 1 state.
The verdict
NCT07301216, a study of Wilson Disease, is actively recruiting participants, sponsored by Yale University.
- RECRUITING
- Registry status
- 30 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a prospective study that will determine the optimal timing for 24-hour urinary copper excretion (UCE) measurement after temporary discontinuation of standard therapies in Wilson Disease (WD) patients. The primary objective is to assess whether off-treatment UCE (OT-UCE) correlates with non-ceruloplasmin-bound copper (NCC) levels, aiming to validate OT-UCE as a surrogate marker for systemic copper bioavailability and disease stability. Stable WD patients will be enrolled, temporarily taken off treatment under close monitoring, and undergo UCE and NCC testing. If OT-UCE is validated, it could serve as a practical biomarker for monitoring WD treatment and stability in clinical practice and future trials.
Conditions Studied
Study Locations (1)
Connecticut
- Yale School of Medicine - New Haven
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2026-01-08 |
| Est. Completion | 2028-09-30 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07301216
The ClinicalTrials.gov registry entry for NCT07301216 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 119-participant average among 4 other Wilson Disease trials with a reported enrollment target (75% lower). The listed sponsor is Yale University, which has 1,492 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Wilson Disease appearing as the primary indexed condition, and to 0 interventions.
NCT07301216 reports 1 study location spanning 1 distinct geographic area - top geographies include Connecticut.
Frequently Asked Questions
What is clinical trial NCT07301216 about?
NCT07301216 is a clinical study titled "Off Treatment Urinary Copper Excretion in Wilson Disease, Pilot Study". This is a prospective study that will determine the optimal timing for 24-hour urinary copper excretion (UCE) measurement after temporary discontinuation of standard therapies in Wilson Disease (WD) patients. The primary objective is to assess whether off-treatment UCE (OT-UCE) correlates with non-c...
What is the current status of trial NCT07301216?
This trial is currently recruiting. The enrollment target is 30 participants. The study started on 2026-01-08. Estimated completion is 2028-09-30.
What conditions does trial NCT07301216 study?
This clinical trial studies the following conditions: Wilson Disease.
Who is sponsoring clinical trial NCT07301216?
This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07301216 being conducted?
This trial has 1 study location across Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Wilson Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Prescreening Study to Identify Potential Wilson Disease Participants for Gene-Editing Clinical Trial
RECRUITING
-
Natural History of Wilson Disease
RECRUITING
-
A Phase 1/2/3 Study of UX701 Gene Therapy in Adults With Wilson Disease
ACTIVE NOT RECRUITING · Phase 1
-
The Assessment of Copper Parameters in Wilson Disease Participants on Standard of Care Treatment
COMPLETED
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.